BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Orion Corporation readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Orion Corporation's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07288398-601@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Simdax (Levosimendan): Phase 3 readout est. (NCT07288398)
DESCRIPTION:Simdax (Levosimendan)\, phase 3\, Pulmonary Hypertension due to
  Left Heart Disease.\nStudy: LEVEL-2: LEVosimendan to Improve Exercise Lim
 itation in Patients With PH-HFpEF-2\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/levosimendan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07288
 398
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436689-601@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Simdax (Levosimendan): Phase 3 readout est. (NCT07436689)
DESCRIPTION:Simdax (Levosimendan)\, phase 3.\nStudy: Long-Term Open-Label E
 xtension Study of Oral Levosimendan\nEstimated primary completion: March 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/levosimendan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0743668
 9
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
